Croton cajucara: Patents and Nanotechnological Advances.
Croton cajucara Benth
Nanotechnology
Nanotechnology advances
New pharmacological perspectives
Patents
Trans-dehydrocrotonin (t-DCNT)
Journal
Recent patents on nanotechnology
ISSN: 2212-4020
Titre abrégé: Recent Pat Nanotechnol
Pays: United Arab Emirates
ID NLM: 101291922
Informations de publication
Date de publication:
16 Aug 2023
16 Aug 2023
Historique:
received:
22
12
2022
revised:
22
06
2023
accepted:
17
07
2023
medline:
17
8
2023
pubmed:
17
8
2023
entrez:
17
8
2023
Statut:
aheadofprint
Résumé
Croton cajucara Benth showed several pharmacological properties such as: anti-inflammatory, antinociceptive hypoglycemic, lipid-lowering, antiulcer, antiestrogenic, antitumor, antigenotoxic, antimutagenic, and cardiovascular. The 19-nor-clerodane diterpene trans-dehydrocrotonin (t-DCTN or DCTN) is the major bioactive constituent extracted from the bark of this Croton. Patents for Croton cajucara Benth in the period 2015 to 2022 comprises 14 published documents. Among them 4 patents are colloidal systems (SM/SNEDDS) loading t-DCTN for pharmacological applications. Patent registrations highlighted the huge promising biotechnological potential of Croton cajucara Benth especially in the phytotherapy field, and the correlation with its bioactive constituents of which t-DCTN showed the foremost results, so this herbal could become an alternative in the treatment of Covid-19. However, investigation of more recently published patents for clerodane diterpenes with similar chemical structure of t-DCTN, who previously showed antiviral property must be carried out and should be searched on several patent data bases.
Identifiants
pubmed: 37587801
pii: NANOTEC-EPUB-133626
doi: 10.2174/1872210517666230816090220
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.